Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

P.J. Lugtenburg, P.D. Brown, B. van der Holt, F.A. D'Amore, H.R. Koene, E. de Jongh, R. Fijnheer, J.W. van Esser, L.H. Bohmer, J.F. Pruijt, G.E. Verhoef, M. Hoogendoorn, M.Y. Bilgin, M. Nijland, N.C. van der Burg-de Graauw, M. Oosterveld, K.S.G. Jie, T.S. Larsen, M.W. van der Poel, M.B. LeijsM.H. Silbermann, M.V. Kooy, A. Beeker, M.J. Kersten, J.K. Doorduijn, L.W. Tick, R.E. Brouwer, K.H. Lam, C.N. Burggraaff, B. de Keizer, A.I. Arens, D. de Jong, O.S. Hoekstra, J.M. Zijlstra-Baalbergen

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)
Original languageEnglish
Number of pages18
JournalJournal of Clinical Oncology
Volume38
Issue number29
DOIs
Publication statusPublished - 10 Oct 2020

Keywords

  • chemotherapy
  • dose-dense rituximab
  • doxorubicin
  • elderly-patients
  • exposure
  • non-hodgkin-lymphoma
  • optimization
  • plus cyclophosphamide
  • response assessment
  • vincristine
  • RESPONSE ASSESSMENT
  • DOXORUBICIN
  • CHEMOTHERAPY
  • PLUS CYCLOPHOSPHAMIDE
  • DOSE-DENSE RITUXIMAB
  • VINCRISTINE
  • NON-HODGKIN-LYMPHOMA
  • OPTIMIZATION
  • ELDERLY-PATIENTS
  • EXPOSURE

Cite this